1-5 of 5
Chan Gao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, Shun Lu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 461–467.
https://doi.org/10.1158/1078-0432.CCR-21-2936
Published: 01 February 2022
View article titled, Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Open the PDF for Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial in another window
Includes: Supplementary data
Journal Articles

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC

Kai Zhang, Xiaohua Hong, Zhengbo Song, Yu Xu, Chengcheng Li, Guoqiang Wang, Yuzi Zhang, Xiaochen Zhao, Zhengyi Zhao, Jing Zhao, Mengli Huang, Depei Huang, Chuang Qi, Chan Gao, Shangli Cai, Feifei Gu, Yue Hu, Chunwei Xu, Wenxian Wang, Zhenkun Lou, Yong Zhang, Li Liu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (14): 3649–3661.
https://doi.org/10.1158/1078-0432.CCR-19-3976
Published: 15 July 2020
View article titled, Identification of Deleterious <em>NOTCH</em> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
Open the PDF for Identification of Deleterious <em>NOTCH</em> Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC in another window
Includes: Supplementary data
Journal Articles

Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses

Mauricio S. Caetano, Ahmed I. Younes, Hampartsoum B. Barsoumian, Michael Quigley, Hari Menon, Chan Gao, Thomas Spires, Timothy P. Reilly, Alexandra P. Cadena, Taylor R. Cushman, Jonathan E. Schoenhals, Ailin Li, Quynh-Nhu Nguyen, Maria Angelica Cortez, James W. Welsh
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7576–7584.
https://doi.org/10.1158/1078-0432.CCR-19-0795
Published: 13 December 2019
View article titled, Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses
Open the PDF for Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses in another window
Includes: Supplementary data
Journal Articles

Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Li Li, Liyan Jiang, Yubo Wang, Yizhuo Zhao, Xiao-Ju Zhang, Guoming Wu, Xiangdong Zhou, Jianguo Sun, Jun Bai, Biyong Ren, Kun Tian, Zhi Xu, Hua-liang Xiao, Qi Zhou, Rui Han, Hengyi Chen, Haidong Wang, Zhenzhou Yang, Chan Gao, Shangli Cai, Yong He
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 6967–6975.
https://doi.org/10.1158/1078-0432.CCR-19-0437
Published: 02 December 2019
View article titled, Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Open the PDF for Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial in another window
Includes: Supplementary data
Journal Articles

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

Rui Wang, Chan Gao, Megan Raymond, Gennaro Dito, Dominic Kabbabe, Xiao Shao, Ed Hilt, Yongliang Sun, Irene Pak, Martin Gutierrez, Ignacio Melero, Anna Spreafico, Richard D. Carvajal, Michael Ong, Anthony J. Olszanski, Christina Milburn, Kent Thudium, Zheng Yang, Yan Feng, Paula M. Fracasso, Alan J. Korman, Praveen Aanur, Shih-Min A. Huang, Michael Quigley
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6709–6720.
https://doi.org/10.1158/1078-0432.CCR-19-0526
Published: 15 November 2019
View article titled, An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Open the PDF for An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data